Please assess the completion status of the following clinical trial:

Trial Title: Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥2 months and less than 3 months on the day of first study vaccine administration~* Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg~* Informed consent form has been signed and dated by the parent or other legally acceptable representative~* Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Participation in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure~* Receipt or planned receipt of any vaccine in the 4 weeks preceding or following any trial vaccination (except Diphtheria, Tetanus, acellular Pertussis vaccine \[DTaP\], Haemophilus Influenzae Type b \[Hib\] vaccine, bacille Calmette-Guerin vaccine \[BCG\] and Hepatitis B given at least 7 days before and after study vaccination)Previous vaccination against poliomyelitis with either the trial vaccine or another vaccine~* Receipt of immune globulins, blood or blood-derived products since birth~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy since birth; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks since birth)~* Congenital or acquired immunodeficiency in close contacts to the subjects~* History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)~* At high risk for human immunodeficiency virus (HIV) infection during the trial~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances~* Laboratory-confirmed or otherwise known thrombocytopenia, contraindicating intramuscular vaccination~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination~* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion~* Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature ≥37.1°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided~* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study~* Any other contraindication as listed in the study vaccines' leaflets.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 2 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Sequential 1): IPV-OPV-OPV (Type: EXPERIMENTAL): Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
- Group B (Sequential 2): IPV-IPV-OPV (Type: EXPERIMENTAL): Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
- Group C (Reference): OPV-OPV-OPV (Type: EXPERIMENTAL): Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete